Cell and Tissue Banking

, Volume 13, Issue 4, pp 569–575

Establishing a cGMP pancreatic islet processing facility: the first experience in Iran

  • Bagher Larijani
  • Babak Arjmand
  • Mahsa M. Amoli
  • Ziliang Ao
  • Ali Jafarian
  • Mitra Mahdavi-Mazdah
  • Hossein Ghanaati
  • Reza Baradar-Jalili
  • Sasan Sharghi
  • Abbas Norouzi-Javidan
  • Hamid Reza Aghayan
Article

Abstract

It has been predicted that one of the greatest increase in prevalence of diabetes will happen in the Middle East bear in the next decades. The aim of standard therapeutic strategies for diabetes is better control of complications. In contrast, some new strategies like cell and gene therapy have aimed to cure the disease. In recent years, significant progress has occurred in beta-cell replacement therapies with a progressive improvement of short-term and long term outcomes. In year 2005, considering the impact of the disease in Iran and the promising results of the Edmonton protocol, the funding for establishing a current Good Manufacturing Practice (cGMP) islet processing facility by Endocrinology and Metabolism Research Center was approved by Tehran University of Medical Sciences. Several islet isolations were performed following establishment of cGMP facility and recruitment of all required equipments for process validation and experimental purpose. Finally the first successful clinical islet isolation and transplantation was performed in September 2010. In spite of a high cost of the procedure it is considered beneficial and may prevent long term complications and the costs associated with secondary cares. In this article we will briefly describe our experience in setting up a cGMP islet processing facility which can provide valuable information for regional countries interested to establish similar facilities.

Keywords

Clean room Clinical grade cGMP Pancreatic islet 

References

  1. Akrami SM, Osati Z, Zahedi F, Raza M (2004) Brain death: recent ethical and religious considerations in Iran. Transpl Proc 36:2883–2887CrossRefGoogle Scholar
  2. Burger SR (2003) Current regulatory issue in cell and tissue therapy. Cytptherapy 5(4):289–298CrossRefGoogle Scholar
  3. Esteghamati A, Gouya MM, Abbasi M et al (2008) Prevalence of diabetes and impaired fasting glucose in the adult population of Iran. Diabetes Care 31(1):96–98PubMedCrossRefGoogle Scholar
  4. Giordano R, Lazzari L, Rebulla P (2004) Clinical grade cell manipulation. Vox Sang 87:65–72PubMedCrossRefGoogle Scholar
  5. Hengster P, Hermann M, Pirkebner D et al (2005) Islet isolation and GMP, ISO 9001:2000: what do we need—a 3-year experience. Transpl Proc 37:3407–3408CrossRefGoogle Scholar
  6. Hirshberg B, Rother KI, Harlan DM (2003) Islet transplantation: where do we stand now? Diabetes Metab Res Rev 19:175–178PubMedCrossRefGoogle Scholar
  7. Ichii H, Ricordi C (2009) Current status of islet cell transplantation. J Hepatobiliary Pancreat Surg 16:101–112PubMedCrossRefGoogle Scholar
  8. Ikemoto T, Matsumoto S, Itoh T et al (2010) Assessment of islet quality following international shipping of more than 10,000 Km. Cell Transplant 19(6):731–741PubMedCrossRefGoogle Scholar
  9. Langer RM (2010) Islet transplantation: lessons learned since the edmonton breakthrough. Transpl Proc 42:1421–1424CrossRefGoogle Scholar
  10. Larijani B, Maleckzadeh H, Pajoohi M et al (2003) Prevalence of diabetes mellitus & impaired glucose tolerance of population aged over 25 in Qazvin. J Qazvin Univ Med Sci 26:41–45Google Scholar
  11. Larijani B, Zahedi F, Taheri E (2004) Ethical and legal aspects of organ transplantation in Iran. Transpl Proc 36:1241–1244CrossRefGoogle Scholar
  12. Mahdavi-Mazdeh M, Heidary Rouchi A, Rajolani H et al (2008) Transplantation registry in Iran. Transpl Proc 40:126–128CrossRefGoogle Scholar
  13. Noguchi H, Matsumoto S (2008) Islet transplantation at the Diabetes Research Institute Japan. J Hepatobiliary Pancreat Surg 15:278–283PubMedCrossRefGoogle Scholar
  14. Rezagholizadeh A, Heshmat R, Larijani B (2007) Iranian diabetes guidelines: methods and objectives. Iran J Diabetes Lipid Disord 7(1):115–120Google Scholar
  15. Shapiro J (2002) Eighty years after insulin: parallels with modern islet transplantation. JAMC 167(12):1398–1400Google Scholar
  16. Shapiro AMJ, Ricordi C, Hering BJ et al (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355:1318–1330PubMedCrossRefGoogle Scholar
  17. Sotta ED, Madalozzo TM, Percegona L et al (2004) Establishing an islet transplantation program in a developing country. Transpl Proc 36:1700–1703CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Bagher Larijani
    • 1
  • Babak Arjmand
    • 1
    • 2
  • Mahsa M. Amoli
    • 1
  • Ziliang Ao
    • 3
  • Ali Jafarian
    • 4
  • Mitra Mahdavi-Mazdah
    • 5
  • Hossein Ghanaati
    • 6
  • Reza Baradar-Jalili
    • 7
  • Sasan Sharghi
    • 1
  • Abbas Norouzi-Javidan
    • 2
  • Hamid Reza Aghayan
    • 1
    • 2
  1. 1.Endocrinology and Metabolism Research CenterTehran University of Medical Sciences, Shariati HospitalTehranIran
  2. 2.Brain and Spinal Cord Injury Repair Research CenterTehran University of Medical Sciences, Imam Khomeini HospitalTehranIran
  3. 3.Human Islet Isolation LaboratoryThe University of British ColombiaVancouverCanada
  4. 4.Department of Liver TransplantationImam Khomeini HospitalTehranIran
  5. 5.Department of nephrology and Iranian Tissue BankImam Khomeini Hospital, Tehran University of Medical SciencesTehranIran
  6. 6.Department of RadiologyMedical Imaging Center, Imam Khomeini HospitalTehranIran
  7. 7.Department of SurgeryUniversity of British ColumbiaVancouverCanada

Personalised recommendations